Failure to Obtain Informed Consent for Psychotropic Medications
Summary
The facility failed to obtain informed consent for psychotropic medications for Residents 12, 16, 17, and 29. The cited policy stated that residents were not to receive psychotropic drugs unless necessary for a specific diagnosed condition, that indications and targeted symptoms were to be documented, and that residents and/or their representatives were to be educated on the risks, benefits, and alternatives to psychotropic drug use. The survey found that the facility did not have evidence of informed consent for the psychotropic medications actually ordered and administered to these residents. Resident 12 had cognitive impairment and a traumatic brain injury, required assistance with bed mobility, transfers, toileting, bathing, and dressing, and received antipsychotic, antidepressant, and hypnotic medications. The resident’s care plan stated psychotropic medication was used for behavior management and that the resident/family/caregivers were to be educated about risks, benefits, side effects, and toxic symptoms. However, the informed consent form on file listed Seroquel 25 mg 1/2 tablet daily, while the active orders showed Seroquel 50 mg daily, Ativan 1 mg daily, Buspirone 5 mg twice daily, Lorazepam oral concentrate as needed, Sertraline 50 mg daily, and Trazodone 50 mg daily. The DON confirmed there was no evidence of informed consent for the current Seroquel dose or for the other psychotropic medications. Resident 16 had cognitive impairment, dementia, used a walker and wheelchair, required assistance with transfers, toileting, bathing, and dressing, and had bed, chair, and wander alarms in use. The resident’s care plan identified antipsychotic and antianxiety medication use for behavior management and stated the resident/family/caregiver were to be educated about risks, benefits, and side effects. The active medication orders included Lorazepam 0.5 mg daily and Quetiapine 50 mg twice daily, and the DON confirmed there was no evidence of informed consent for either medication. Resident 29 had dementia, anxiety, depression, and Parkinson’s disease, required assistance with bathing, dressing, hygiene, toileting, bed mobility, and transfers, and had mood, behavior, and hallucination concerns. Consent on file covered Seroquel 25 mg daily, but the active orders showed Quetiapine 50 mg daily and Duloxetine 60 mg daily, and the DON confirmed there was no evidence of consent for the current Quetiapine dose or for Duloxetine. Resident 17 had severe cognitive impairment, Alzheimer’s dementia, anxiety, and depression; consent was obtained for Sertraline 25 mg, but the active order was Sertraline 50 mg daily, and the DON confirmed there was no evidence of signed informed consent for the increased dose.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.